Ntombiyethu Biyase

Dr. Ntombiyethu Biyase


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2022 in Journal of Orthopaedic Surgery and Research
Verified
Journal Article
Open access
PDF file
MSMpumelelo Sibanyoni
Mpumelelo Sibanyoni
NBNtombiyethu Biyase
Ntombiyethu Biyase
PCPalesa Motshabi Chakane
Palesa Motshabi Chakane
Background and purpose of the study: Intrathecal morphine (ITM) provides optimal postoperative analgesia in patients who are scheduled for total knee and hip operation with spinal anaesthesia. However, the ideal dose at which maximal analgesic effect occurs with minimal side effects is not known. This study aimed to describe the use of two doses of ITM and side effect profile in patients undergoing elective hip and knee arthroplasty. Methods: This was a prospective, descriptive, and contextual study conducted on patients who had total hip and knee replacement at Chris Hani Baragwanath Academic Hospital from 1 September to 30 November 2020. The sample size consisted of 66 patients who were 18 years and older, American Society of Anaesthesiology (ASA) classification 1–3, patients who had received either 100 mcg or 150 mcg ITM dose under spinal anaesthesia and sent to the ward postoperatively. Visual Analogue Scale (VAS) score was used to assess pain in the first 24 h, consumption of rescue analgesia and reported side effects were documented. Results: There was no relationship between age, weight, ASA classification or type of surgery and VAS score classification groups. Patients who received 100 mcg ITM had a higher median VAS pain score 2 (1–5) compared to those who received 150 mcg ITM 1 (0–2), p = 0.01. The need for rescue analgesia between the two groups was marginally less in the 150 mcg ITM group (p = 0.098). There was no difference in the rate of side effects between the 100 mcg ITM group [12 (41%)] and the 150 mcg ITM group [17 (59%)], p = 0.92. Rescue analgesia was marginally different between groups, p = 0.09. There were no real differences in the VAS pain scores between the total knee and total hip surgeries. None of the patients experienced clinically significant respiratory depression. Conclusion: The 150 mcg ITM dose provided good analgesic effects with longer duration of action and comparable side effect profile to the 100 mcg ITM dose. This dose was not associated with development of respiratory depression and can therefore be administered safely to patients who are discharged to the ward postoperatively in a resource constraint environment.

17 March 2021 in Southern African Journal of Critical Care
Verified
Journal Article
Open access
PDF file
NBNtombiyethu Biyase
Ntombiyethu Biyase
HPH Perrie
H Perrie
JSJ Scribante
J Scribante
MMM Muteba
M Muteba
SCS Chetty
S Chetty
Stress ulcer prophylaxis use in critical care units at public hospitals in Johannesburg, South Africa

19 November 2020 in Southern African Journal of Anaesthesia and Analgesia
Verified
Journal Article
Open access
NBNtombiyethu Biyase
Ntombiyethu Biyase
Contrast agents have long been used for the imaging of anatomic boundaries and to explore normal and abnormal physiologic findings. The introduction of increasingly faster and more discriminating radiographic imaging techniques has resulted in the need for radiation-attenuating contrast agents that can be used in traditional radiographic imaging or, more recently, in subtraction imaging, both of which can be projected and rotated in three dimensions. By far the most successful and widely applied contrast agents in use today are the iodinated contrast agents (ICAs), first introduced into clinical practice in the 1950s.1 It is estimated that approximately 75 million doses of ICAs are given worldwide each year.

17 September 2026 in Southern African Journal of Critical Care
Verified
Journal Article
Open access
PDF file
NMN R Msimango
N R Msimango
NBNtombiyethu Biyase
Ntombiyethu Biyase
SDSithandiwe Dingezweni
Sithandiwe Dingezweni
Background. Coronavirus disease‐2019 (COVID‐19) is associated with a heightened inflammatory response, leading to thromboembolic events that influence patient outcomes. Complex anticoagulation strategies are often required to mitigate these complications. However, severe illness combined with such strategies may be associated with bleeding at multiple sites. Objectives. To describe the incidence of bleeding and venous thromboembolism (VTE) in critically ill COVID‐19 patients receiving anticoagulation. Secondary objectives were to determine the incidence of transfusion in bleeding patients, and the association between inflammatory markers, coagulation parameters, and bleeding and/or VTE. Length of intensive care unit (ICU) stay and patient outcomes in the same cohort were also investigated. Methods. Participants included adult patients with confirmed COVID‐19 by positive polymerase chain reaction (PCR), admitted to the ICU from 1 April 2020 to 30 April 2021. A p‐value of <0.05 was considered statistically significant. Results. The study population comprised 103 patients. The anticoagulant of choice was low‐molecular‐weight heparin at therapeutic doses (median 80 mg/day). Bleeding occurred in 39.8% (n=41) of patients, predominantly from the oral mucosa (20.4%; n=21) and the gastrointestinal tract (13.6%; n=14). Of the patients who bled, 46.3% (n=19) received blood transfusions. Two patients (1.9%) developed grade 1 deep vein thrombosis. The median length of ICU stay was 7 days. Survival dropped below 50% (n=51) after 10 days of admission, and 25% (n=25) of patients survived beyond 28 days. Overall mortality was high at 65.0% (n=67). Conclusion. COVID‐19‐positive critically ill patients receiving therapeutic anticoagulation exhibited an increased incidence of bleeding, accompanied by a high mortality rate.

17 February 2022 in Research Square
Verified
Preprint
Open access
PDF file
MSMpumelelo Sibanyoni
Mpumelelo Sibanyoni
NBNtombiyethu Biyase
Ntombiyethu Biyase
PCPalesa Motshabi Chakane
Palesa Motshabi Chakane
Background and purpose of the study: Intrathecal morphine (ITM) provides optimal postoperative analgesia in patients who are scheduled for total knee and hip operation with spinal anaesthesia. However, the ideal dose at which maximal analgesic effect occurs with minimal side effects is not known. This study aimed to describe the use of two doses of ITM, and side effect profile in patients undergoing elective hip and knee arthroplasty.Methods: This was a prospective, descriptive, and contextual study conducted on patients who had total hip and knee replacement at Chris Hani Baragwanath Academic Hospital from 1 September to 30 November 2020. The sample size consisted of 66 patients who were 18 years and older, American Society of Anaesthesiology (ASA) classification 1-3, patients who had received either 100 mcg or 150 mcg ITM dose under spinal anaesthesia and sent to the ward postoperatively. Visual Analogue Scale (VAS) score was used to assess pain in the first 24 hours, consumption of rescue analgesia and reported side effects were documented.Results: There was no relationship between age, weight, ASA classification or type of surgery and VAS score classification groups. Patients who received 100 mcg ITM had a higher median VAS pain score 2 (1-5) compared to those who received 150 mcg ITM 1 (0-2), p = 0.01. The need for rescue analgesia between the two groups was marginally less in the 150mcg ITM group (p =0.098). There was no difference in the rate of side effects between the 100 mcg ITM group [12 (41%)] and the 150 mcg ITM group [17 (59%)], p = 0.92. Rescue analgesia was marginally different between groups, p = 0.09. There were no real differences in the VAS pain scores between the total knee and total hip surgeries. None of the patients experienced clinically significant respiratory depression. Conclusion: The 150mcg ITM dose provided good analgesic effects with longer duration of action and comparable side effect profile to the 100mcg ITM dose. This dose was not associated with development of respiratory depression can therefore be administered safely to patients who are discharged to the ward postoperatively in a resource constraint environment.